Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer

被引:62
作者
Coe, B. P.
Lockwood, W. W.
Girard, L.
Chari, R.
MacAulay, C.
Lam, S.
Gazdar, A. F.
Minna, J. D.
Lam, W. L.
机构
[1] British Columbia Canc Res Ctr, Dept Canc Genet & Dev Biol, Vancouver, BC V5Z 1L3, Canada
[2] Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA
关键词
array CGH; gene expression analysis; cancer genome; non-small cell lung cancer; small cell lung cancer;
D O I
10.1038/sj.bjc.6603167
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is the leading cause of cancer-related mortality in the world, with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) comprising the two major cell types. Although these cell types can be distinguished readily at the histological level, knowledge of their underlying molecular differences is very limited. In this study, we compared 14 SCLC cell lines against 27 NSCLC cell lines using an integrated array comparative genomic hybridisation and gene expression profiling approach to identify subtype-specific disruptions. Using stringent criteria, we have identified 159 of the genes that are responsible for the different biology of these cell types. Sorting of these genes by their biological functions revealed the differential disruption of key components involved in cell cycle pathways. Our novel comparative combined genome and transcriptome analysis not only identified differentially altered genes, but also revealed that certain shared pathways are preferentially disrupted at different steps in these cell types. Small cell lung cancer exhibited increased expression of MRP5, activation of Wnt pathway inhibitors, and upregulation of p38 MAPK activating genes, while NSCLC showed downregulation of CDKN2A, and upregulation of MAPK9 and EGFR. This information suggests that cell cycle upregulation in SCLC and NSCLC occurs through drastically different mechanisms, highlighting the need for differential molecular target selection in the treatment of these cancers.
引用
收藏
页码:1927 / 1935
页数:9
相关论文
共 53 条
[1]  
Amann J, 2005, CANCER RES, V65, P226
[2]   Chromosomal imbalances in human lung cancer [J].
Balsara, BR ;
Testa, JR .
ONCOGENE, 2002, 21 (45) :6877-6883
[3]   EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J].
Adrian P. Bracken ;
Diego Pasini ;
Maria Capra ;
Elena Prosperini ;
Elena Colli ;
Kristian Helin .
The EMBO Journal, 2003, 22 (20) :5323-5335
[4]   Biological functions of the ING family tumor suppressors [J].
Campos, EI ;
Chin, MY ;
Kuo, WH ;
Li, G .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2004, 61 (19-20) :2597-2613
[5]   SeeGH - A software tool for visualization of whole genome array comparative genomic hybridization data [J].
Chi, B ;
deLeeuw, RJ ;
Coe, BP ;
MacAulay, C ;
Lam, WL .
BMC BIOINFORMATICS, 2004, 5 (1)
[6]   Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines [J].
Coe, BR ;
Lee, EHL ;
Chi, B ;
Girard, L ;
Minna, JD ;
Gazdar, AF ;
Lam, S ;
MacAulay, C ;
Lam, WL .
GENES CHROMOSOMES & CANCER, 2006, 45 (01) :11-19
[7]   Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes [J].
de Leeuw, RJ ;
Davies, JJ ;
Rosenwald, A ;
Bebb, G ;
Gascoyne, RD ;
Dyer, MJS ;
Staudt, LM ;
Martinez-Climent, JA ;
Lam, WL .
HUMAN MOLECULAR GENETICS, 2004, 13 (17) :1827-1837
[8]   Human enhancer of invasion-cluster, a coiled-coil protein required for passage through mitosis [J].
Einarson, MB ;
Cukierman, E ;
Compton, DA ;
Golemis, EA .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (09) :3957-3971
[9]   ABSENCE OF HELA-CELL CONTAMINATION IN 169 CELL LINES DERIVED FROM HUMAN TUMORS [J].
FOGH, J ;
WRIGHT, WC ;
LOVELESS, JD .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1977, 58 (02) :209-214
[10]   Minireview: Cyclin D1: Normal and abnormal functions [J].
Fu, MF ;
Wang, CG ;
Li, ZP ;
Sakamaki, T ;
Pestell, RG .
ENDOCRINOLOGY, 2004, 145 (12) :5439-5447